Proteon Therapeutics Announces Third Quarter 2019 Financial Results
31 oct. 2019 17h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (“Proteon” or the “Company”) (Nasdaq: PRTO), a company that has historically focused on the development of novel,...
Proteon Therapeutics and ArTara Therapeutics Agree to Combine
23 sept. 2019 16h20 HE
|
Proteon Therapeutics, Inc.
Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing to be Led by a Syndicate of Healthcare...
Proteon Therapeutics Announces Second Quarter 2019 Financial Results
07 août 2019 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to...
Proteon Therapeutics Announces First Quarter 2019 Financial Results
08 mai 2019 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Review of Potential Strategic Transactions
15 avr. 2019 16h30 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
28 mars 2019 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
13 mars 2019 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 13, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 11th
04 mars 2019 16h30 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease
24 janv. 2019 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Stifel 2018 Healthcare Conference November 13th
08 nov. 2018 07h45 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...